Friday, October 14, 2022 3:28:06 PM
Re-Posting as a reminder! the remaining un-blinded data will have been given the Higher Doses
Ps. Seen this the other day....
Re-Posting as a reminder! $RVV $RVVTF #Bucillamine #Infectiousdiseases #Covid19 #FDA
— Crusader (@Crusade05626773) October 14, 2022
🎯 the remaining un-blinded data will have been given the Higher Doses 😉 pic.twitter.com/N90vLpt0g6
Ps. Seen this the other day....
I'll look out for it, thank you!
— Wency Leung (@wencyleung) October 13, 2022
Recent RVVTF News
- Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures • ACCESS Newswire • 05/20/2026 11:45:00 AM
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
